glp 1 agonists ozempic Comparing Ozempic, Wegovy and Other GLP-1 Drugs Part 2 of a 3-Part

AstraZeneca, Novo Nordisk A/S, Eli Lilly and Company, Sanofi and Hypera S.A

Due to a short plasma half-life of native GLP-1, several synthesized GLP-1 receptor agonists (RAs) were developed for type 2 diabetes mellitus (DM) treatment

With the participation of researchers from the Paul Langerhans Institute Dresden (PLID), partner at the German Center for Diabetes Research, a GLP-1 receptor agonist in the form of tablets could for the first time be compared with the most common second-line therapy of T2D, a DPP-IV inhibitor

In this Review, the authors discuss the potential effects of GLP-1 receptor agonists on the incidence, disease activity and progression of various forms of arthritis, as well as practical considerations for their use in this context.

As 2025 gets underway, we take a look at what lies ahead for the highly dynamic market for effective anti-obesity medications (AOMs)

Further studies are needed to assess the potential cardiovascular and renal benefits of combination therapy and to determine suitable patient population for the therapy